Gilteritinib is used to treat adults with acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation when the disease has come back or has not improved after previous treatment(s).
Nanjing Fred Technology Co., Ltd is a high-tech enterprise engaged in the R&D, production and sales of pharmaceutical intermediates. With our own R&D center and production bases, we specialize in the kg to hundred kgs scale synthesis of complex organic building blocks and bio fragments including APIs, API intermediates and special fine chemicals. We provide high quality products and efficient service for our customers.
We will try our best to satisfy customer’s requirements and build long-term partnerships with customers.
CMO
Sign a confidentiality agreement mutually, the customer provides the existing production technology, and we manufacture the product according to customers’ production technology.
CDMO
1.We conduct the process optimization, small test, pilot test, to commercial production according to the route specified by the customer.
2.The customer only provide the product structure, and we will design the route, optimize the process, small test, pilot test to commercial production.
We are best at:
1.The rapid transformation from small-scale test to commercial production can shorten the production time.
2.Constantly optimize production process to minimize costs, which can help customers finish orders quickly with high quality.
China
